Vericel Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 3/17/2026)
| Balance Sheet | Total Assets | 487,969,000.00 | ROE | 72.68 % |
| Balance Sheet | Total Equity | 354,640,000.00 | ROA | 3.39 % |
| Cashflow | Capital Expenditures | -27,162,000.00 | P/FCF | 84.69 |
| Cashflow | Free Cash Flow | 24,748,000.00 | – | – |
| Cashflow | Operating Cash Flow | 51,910,000.00 | P/CF | 40.37 |
| Income | Earnings per Share (diluted) | 0.32 | Div. Yield | – |
| Income | Net Income | 16,518,000.00 | P/E | 125.78 |
| Income | Shares Outstanding | 52,071,000.00 | P/B | 5.91 |
| Income | Total Revenue | 276,259,000.00 | P/S | 7.59 |
Ratios calculated on: 10/14/2026
Company Description
Vericel Corporation, formerly Aastrom Biosciences, Inc., is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment. Its autologous cell therapy products include Carticel (autologous cultured chondrocytes), which is an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel (cultured epidermal autografts), which is a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns. The Company is developing MACI, which is a third-generation autologous chondrocyte implant and ixmyelocel-T, which is a patient-specific multicellular therapy.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.vcel.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more